West Pharma FY25: GLP-1 Tailwind, $8+ EPS FY26

Thesis

West Pharmaceutical Services (NYSE: WST) crossed $3 billion in annual revenue for the first time in FY25 (December 2025) — revenue $3.074B (+6.2%), FCF $468.9M (+70%), and adjusted EPS growing 8% YoY (GAAP EPS $6.80 was held near-flat by one-time charges; management's adjusted figure is the operative metric). The company is the dominant global supplier of elastomeric components and delivery systems for injectable biologics — the rubber stoppers, closures, and self-injection devices that every prefilled syringe, vial, and autoinjector requires before a drug ships.

The FY25-26 investment thesis is built on three compounding secular tailwinds:

1. GLP-1 injectable boom: Glucagon-like peptide-1 agonists (Ozempic, Wegovy, Mounjaro, Zepbound) are the fastest-growing drug class in the pharmaceutical industry. Every injectable GLP-1 dose requires elastomeric components and delivery devices — WST's highest-margin products. By Q1 FY26, GLP-1-related revenues had grown to 10% of total company sales with significant further runway as penetration rates, dosing regimens, and indications expand. Non-GLP-1 HVP components grew in the high teens in Q1 FY26, showing the broader biologics market is also accelerating.

2. Annex 1 EU regulatory upgrade cycle: The European Union's revised Annex 1 GMP standard for sterile pharmaceutical manufacturing (effective 2023, compliance deadline 2026) requires pharmaceutical manufacturers to upgrade their packaging components to certified high-value products. WST has 375 active HVP upgrade projects underway — a multi-year revenue stream from customers who must convert to premium components regardless of volume conditions.

3. Biologics and biosimilars structural growth: Biologics drugs (monoclonal antibodies, proteins, vaccines, biosimilars) have replaced small-molecule drugs as the primary growth driver in pharmaceutical R&D. Virtually all biologics require injectable delivery. WST is purpose-built for this market: its Daikyo Crystal Zenith containment systems, NovaPeer stoppers, and West Synchrony prefillable syringe systems are designed specifically for sensitive biologics that cannot tolerate standard glass or rubber contamination. Biologics segment grew 26% organically in Q1 FY26.

The momentum accelerated sharply in Q1 FY26: HVP components organic growth 23%, HVP delivery devices organic growth 28%, biologics 26%. Management raised FY26 organic revenue growth guidance from 5-7% to 7-9% and lifted adjusted EPS guidance to $8.40-$8.75 (vs. prior midpoint $8.025).

FY25 Numbers vs FY24 (Annual, USD; December year-end)

FCF recovery (+70%) reflects both operating leverage and a $91M reduction in CapEx as the major facility build-out at Dublin and Germany approached completion. GAAP EPS near-flat masks adjusted EPS growth of ~4-8% — the gap reflects SmartDose-related charges and restructuring items excluded from adj. EPS.

Business Model: Mission-Critical Component Supplier

West Pharmaceutical Services makes the components that hold injectable drugs safe from factory to patient:

• Elastomeric closures and components: Rubber stoppers, plungers, seals for vials, cartridges, and prefilled syringes. These are not commodity products — each must be tested and qualified to the specific drug formulation, as elastomers can interact with sensitive biologics
• High-Value Products (HVP): Premium tier with Daikyo Crystal Zenith (cyclic olefin polymer, silicone-free), NovaPeer (particle-free stoppers), and proprietary coatings — commands significantly higher ASP than standard components
• Delivery devices: Self-injection autoinjectors (SmartDOS), prefillable syringe systems (West Synchrony), and containment systems for GLP-1 pens and biologics auto-dosing
• Contract Manufacturing: Third-party drug handling, filling, and device assembly — Dublin facility now fully operational
• Switching costs: Drug manufacturers qualify WST components at the FDA/EMA submission stage. Switching suppliers requires re-qualification of the drug product itself — a 12-18+ month process at minimum, making WST a near-permanent supplier once qualified

Segment Breakdown

HVP Components (48% of Revenue)

The highest-margin, highest-growth segment — WST's core strategic asset.

FY25 performance: 9% organic growth for the full year; $390M in Q4 FY25 alone. GLP-1 elastomers grew to 9% of total company sales by Q3 FY25, rising to 10% by Q1 FY26. Non-GLP-1 HVP also recovering as biologics destocking (which suppressed FY24 volumes) normalized.

Q1 FY26 acceleration: 23% organic growth — the strongest reading in recent quarters. Both GLP-1 (10% of company sales) and non-GLP-1 high teens grew simultaneously, indicating broad-based demand not solely dependent on one drug category.

Annex 1 tailwind: 375 active HVP upgrade projects. The EU Annex 1 compliance deadline creates non-discretionary upgrade demand — pharma manufacturers must convert standard stoppers to HVP-certified components regardless of market conditions.

Capacity: WST is expanding HVP manufacturing capacity in Germany (hiring and training ramping through FY25-26) to address supply constraints outside GLP-1 that were called out in Q3 FY25. The capacity constraint is a signal of demand strength, not a structural problem.

HVP Delivery Devices (14-15% of Revenue)

Autoinjectors, prefilled syringe systems, and self-injection platforms.

SmartDOS 3.5: The flagship connected auto-injector. SmartDOS 3.5 revenue grew in Q1 FY26; legacy SmartDose 3.5 mL business is being divested (closing mid-2026) — the separation sharpens focus on higher-growth platforms.

West Synchrony: New prefillable syringe system launched FY25 as a fully-verified platform specifically designed for biologics. Reduces qualification burden for drug manufacturers.

Q1 FY26: Organic growth 28% — rebounding sharply after a prior-year incentive fee comparison dragged Q3-Q4 FY25 readings negative. Non-smart dose parts also grew double digits in Q1 FY26.

Standard Products (19-20% of Revenue)

Legacy elastomeric components without the HVP premium designation.

FY25-FY26 dynamics: Essentially flat — standard product customers are gradually converting to HVP under Annex 1 and customer quality requirements. WST benefits from the conversion: HVP commands higher ASP than standard. Management reports an ongoing pipeline of HVP conversion projects from the standard base.

Contract Manufacturing (18-19% of Revenue)

The Dublin facility (Ireland) commenced commercial production in FY25, initially for drug handling; delivery device manufacturing for obesity/GLP-1 market is ramping through FY26. The CGM (continuous glucose monitor) contract, a legacy partnership, exits in H2 FY26 — management expects to backfill the space with higher-margin biologics business.

Q1 FY26: Acceleration Across All Fronts

The Q1 FY26 guidance raise — organic growth upgraded by 200bp just one quarter into the fiscal year — is a strong signal that GLP-1 demand and biologics recovery are running ahead of management's conservative initial planning assumptions.

FY26 Framework

• Organic revenue growth: 7-9% (raised from 5-7% post-Q1 FY26)
• Adjusted EPS: $8.40-$8.75 (midpoint $8.575 = ~+21% vs adj. FY25 ~$7.09)
• HVP components: High single to low double-digit organic growth
• HVP delivery devices: Mid-single digit organic growth post-SmartDose divestiture
• Standard Products: ~Flat
• Contract Manufacturing: ~Flat (CGM contract exit offset by Dublin ramp)
• CapEx: ~$275M (declining as major facilities near completion)
• Tariff impact: Fully mitigated in FY26 (partially mitigated FY25 at $15-20M drag)

Multi-Year Strategic Position

GLP-1 option value is underappreciated: Current GLP-1 revenues at 10% of company sales with growth accelerating. The pipeline of GLP-1 candidates across Eli Lilly (tirzepatide, retatrutide), Novo Nordisk (semaglutide, CagriSema), Roche, Pfizer, AstraZeneca, and others represents an expanding denominator of injectable GLP-1 doses WST will supply. Oral GLP-1 alternatives are in development, but injectable formats dominate the approved and near-launch pipeline through 2028 at minimum. Even partial cannibalization by orals leaves WST with a growing absolute GLP-1 injectable volume for years.

Regulatory moat via qualification lock-in: Once a drug manufacturer qualifies WST components in an FDA/EMA filing, the switching cost is effectively a new drug submission. At 375 active Annex 1 upgrade projects, WST is deepening its qualification lock-in with the European biologics industry simultaneously. This is not a short-term customer relationship — it is a decades-long supply chain dependency.

FCF inflection: The $276M FCF in FY24 (a trough year impacted by destocking and high CapEx) rebounded to $469M in FY25. As CapEx normalizes below $300M and earnings grow toward $8+ adjusted EPS, FCF should reach $550M-$650M by FY27. At current market cap (~$21B), FCF yield is modest at ~2.5% today but grows as the GLP-1 cycle compounds.

Margin expansion architecture: Gross margin expanded 120bp in FY25 (34.7% → 35.9%) despite a year of below-trend growth. As HVP mix continues rising (now 48% of net sales and growing vs. lower-margin standard products and contract manufacturing), the gross margin trajectory points toward 37-39% on a multi-year basis — each mix percentage point shift carries material earnings leverage.

SmartDose divestiture cleans up the portfolio: Exiting the 3.5mL SmartDose platform (closing mid-2026) sharpens focus on HVP components and the West Synchrony/SmartDOS 3.5 next-generation delivery device platform. The divested business was a lower-growth element; removing it allows resource concentration on the highest-ROIC segments.

Risks

• GLP-1 oral drug displacement: Eli Lilly's orforglipron (oral small molecule GLP-1) and other oral candidates could reduce the injectable GLP-1 addressable market if they gain broad approvals and demonstrate comparable efficacy. A 50% shift from injectable to oral GLP-1 by 2028 would reduce WST's 10% GLP-1 revenue contribution materially
• GLP-1 concentration risk: 10% of revenues from a single drug category creates meaningful single-theme exposure; any FDA action on GLP-1 safety, coverage restriction, or demand shock would disproportionately affect WST
• CGM contract headwind H2 FY26: The exit of the CGM contract (continuous glucose monitor manufacturing) creates a revenue gap in Contract Manufacturing in H2 FY26; management must backfill with higher-margin business, but execution is uncertain
• Biologics destocking recurrence: FY24 saw a pharma destocking cycle that suppressed HVP demand; if pharma companies rebuild inventory ahead of demand or reduce purchases during drug development slowdowns, growth can stall
• Tariff and FX risk: WST manufactures in the US, Germany, Ireland, Singapore, and Brazil; tariff escalation on imported components or FX movements (especially EUR/USD) create P&L volatility
• Valuation: At ~$21B market cap and 7x forward revenue, WST trades at a premium to industrial peers; any guidance miss or GLP-1 growth deceleration creates downside risk disproportionate to the earnings miss

Citations

• WST FY25 financial statements (drillr financial_statements; period_end 2025-12 FY)
• WST FY24 financial statements (drillr financial_statements; period_end 2024-12 FY)
• Q4 FY25 earnings call (~2026-02): First $3B+ revenue year; 4%+ organic growth; FCF +70%; adj EPS +8%; 2026 guide: 5-7% organic, adj EPS $8.025 midpoint; West Synchrony launched; SmartDose 3.5 mL divestiture announced
• Q3 FY25 earnings call (~2025-10): Revenue $805M +5% organic; adj EPS $1.96 +6%; HVP components +13% organic; GLP-1 = 9% of total revenues; 375 Annex 1 projects; new CFO Bob McMahon; Dublin obesity production ramping
• Q2 FY25 earnings call (~2025-07): HVP components +11.3% organic; Q2 guidance raised to $6.65-$6.85 adj EPS; delivery devices +30%; tariff impact mitigated to $15-20M
• Q1 FY26 earnings call (~2026-04): HVP components +23% organic; GLP-1 = 10% company sales; biologics +26%; FY26 guidance raised to 7-9% organic, adj EPS $8.40-$8.75; Q2 guide $830-$850M revenue, adj EPS $2.05-$2.12